Compounds > threonine

threonine and ixazomib

threonine has been researched along with ixazomib in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Appel, A1
Hu, Y; Wu, P; Zhang, J1
Bourenkov, G; Chari, A; Henneberg, F; Mata, RA; Schneider, TR; Schrader, J; Stark, H; Tittmann, K1
Hasinoff, BB; Patel, D1
Hawkins, CJ; Patatsos, K; Shekhar, TM1
Agha, A; Ali, AA; Debiec-Rychter, M; Dhillon, HS; Duensing, A; Gebreyohannes, YK; Lee, DM; Makielski, KR; Mehalek, KR; Patil, SS; Rausch, JL; Schöffski, P; Tolstov, Y; Wellens, J; Wozniak, A1

Reviews

1 review(s) available for threonine and ixazomib

ArticleYear
Clinical and marketed proteasome inhibitors for cancer treatment.
    Current medicinal chemistry, 2013, Volume: 20, Issue:20

    Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine

2013

Other Studies

5 other study(ies) available for threonine and ixazomib

ArticleYear
Drugs: More shots on target.
    Nature, 2011, Dec-14, Volume: 480, Issue:7377

    Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine

2011
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
    Science (New York, N.Y.), 2016, Aug-05, Volume: 353, Issue:6299

    Topics: Antineoplastic Agents; Biocatalysis; Boron Compounds; Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; Drug Design; Glycine; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Threonine

2016
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
    Cardiovascular toxicology, 2018, Volume: 18, Issue:6

    Topics: Animals; Animals, Newborn; Boron Compounds; Boronic Acids; Bortezomib; Cardiotoxicity; Cell Survival; Dose-Response Relationship, Drug; Epoxy Compounds; Glycine; Humans; K562 Cells; Ketones; Kinetics; Myocytes, Cardiac; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Rats, Sprague-Dawley; Threonine

2018
Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
    Veterinary and comparative oncology, 2018, Volume: 16, Issue:4

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bone Neoplasms; Boron Compounds; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Glycine; Humans; Oligopeptides; Osteosarcoma; Proteasome Inhibitors; Sulfonamides; Threonine

2018
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
    Scientific reports, 2020, 03-20, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Boronic Acids; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Oligopeptides; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Threonine; Xenograft Model Antitumor Assays

2020